Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostar plus cisplatin in malignant pleural effusion
NCT04914598Phase 3Active, not recruiting
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Jul 2021
- Primary completion
- Feb 2025
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in malignant pleural effusion (MPE) comparing ENDOSTAR + cisplatin with Placebo + cisplatin (2 arms). Primary endpoint: Puncture/drainage-Free Survival at 6 months. Started Jul 2021; status: active, not recruiting.
02
Drugs
endostar
03
Conditions
malignant pleural effusion (MPE)
Beyond the preview
Go deeper on NCT04914598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04914598.